Cargando…
Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
Irritable bowel syndrome (IBS) is one of the most common disorders of the gut-brain axis, which affects approximately 4% of the global population. The Rome IV criteria define IBS as chronic or recurrent abdominal pain associated with altered bowel habits. Patients can be categorized in four subtypes...
Autores principales: | Colomier, Esther, Algera, Joost, Melchior, Chloé |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935509/ https://www.ncbi.nlm.nih.gov/pubmed/33679391 http://dx.doi.org/10.3389/fphar.2020.629026 |
Ejemplares similares
-
Irritable bowel syndrome with food‐related symptoms: Future directions in the clinical management
por: Melchior, Chloé, et al.
Publicado: (2022) -
The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence
por: Algera, Joost, et al.
Publicado: (2019) -
Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome
por: Algera, Joost P., et al.
Publicado: (2022) -
Irritable bowel syndrome: Factors of importance for disease‐specific quality of life
por: Melchior, Chloé, et al.
Publicado: (2022) -
An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhen, Zhang, et al.
Publicado: (2021)